NICE verdict on Trodelvy threatens unequal access to drug in...

In draft guidance, NICE has said it cannot recommend Gilead Sciences' Trodelvy in triple-negative breast cancer (TNBC), setting up a disparity in access to the drug via the NHS in the UK.

How does HTA for orphan drugs differ across Europe?

New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines across Europe.

England is risking its own opioid epidemic, says PHE

The shadow of Brexit on speed of access

No-one can miss the ongoing saga that is the UK’s exit from the European Union (EU).

The new CDF - Navigating Cancer Drug Access in England

On July 29th 2016, the new process in England for cancer drugs seeking license went live - changing both the shape and potential requirements of the submissions process.